How Does the Guselkumab Data Align With the STRIDE II Guidelines?

In this video, Erin Darguzas, NP, from the Inflammatory Bowel Disease Center at Northwestern Medicine, discusses how Guselkumab data aligns with STRIDE II guidelines for monitoring IBD (Inflammatory Bowel Disease) patients over time. Developed by International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) members, STRIDE II provides a treat-to-target framework that outlines short-term, intermediate, and long-term goals for achieving disease control.

Erin explains how Guselkumab's clinical trials align with these treatment targets. In induction studies, patients were evaluated at Baseline and Week 12, with clinical remission as the primary outcome—matching STRIDE II's short-term targets. The results showed symptom improvement and mucosal healing by Week 12, supporting early treatment efficacy.

In maintenance trials, clinical responders from the induction phase were randomized into maintenance arms, with Week 44 clinical remission as the primary endpoint. Additional key outcomes included corticosteroid-free remission, sustained clinical response, endoscopic improvement, and mucosal healing—meeting intermediate and long-term STRIDE II targets.

By demonstrating both short- and long-term efficacy, Guselkumab shows potential for long-term IBD management in alignment with STRIDE II treatment goals. For more expert insights on IBD treatment strategies, visit the Gastroenterology & Hepatology Advanced Practice Provider (GHAPP) website.

Subscribe for more IBD updates!
#IBD #InflammatoryBowelDisease #Guselkumab #STRIDEII #Gastroenterology #Crohns #UlcerativeColitis #MucosalHealing